Fifth Third Bancorp Makes New Investment in LifeStance Health Group, Inc. $LFST

Posted by George Bondi on Jul 28th, 2026

Fifth Third Bancorp acquired a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 118,561 shares of the company’s stock, valued at approximately $755,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of LifeStance Health Group by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after acquiring an additional 3,086,506 shares during the last quarter. Silversmith Partners I GP LLC bought a new stake in LifeStance Health Group in the 4th quarter valued at $100,842,000. Dimensional Fund Advisors LP increased its holdings in LifeStance Health Group by 6.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 8,906,465 shares of the company’s stock valued at $62,704,000 after acquiring an additional 542,858 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in LifeStance Health Group by 27.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock worth $43,071,000 after purchasing an additional 1,324,691 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays boosted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of LifeStance Health Group in a research note on Wednesday, May 27th. Finally, KeyCorp upped their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Check Out Our Latest Report on LFST

Insiders Place Their Bets

In other news, Director Darren M. Black sold 5,899,661 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the sale, the director directly owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This trade represents a 20.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Eric Shuey sold 243,362 shares of LifeStance Health Group stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the completion of the transaction, the director owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. This trade represents a 21.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 7,687,394 shares of company stock valued at $63,579,701 over the last ninety days. 3.50% of the stock is owned by insiders.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $10.88 on Tuesday. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $11.76. The stock has a market capitalization of $4.22 billion, a P/E ratio of 181.33 and a beta of 1.12. The firm has a fifty day simple moving average of $9.39 and a two-hundred day simple moving average of $7.85. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. LifeStance Health Group’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, analysts expect that LifeStance Health Group, Inc. will post 0.12 earnings per share for the current fiscal year.

LifeStance Health Group Profile

(Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.